Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bernardini Nicoletta, Dattola Annunziata, Gemma Giuseppe Paolo Antonio, Atzori Laura, Artosi Fabio, Biondi Gabriele, Campione Elena, Cuccia Aldo, Dessi Paolo, Di Cesare Antonella, Dragotto Martina, Frau Alessia, Giordano Domenico, Mazzotta Annamaria, Megna Matteo, Michelucci Alessandra, Montesu Maria Antonia, Mugheddu Cristina, Orsini Corinne, Pagnanelli Gianluca, Panduri Salvatore, Persechino Severino, Potestio Luca, Prignano Francesca, Ricceri Federica, Rizzuto Giuseppe, Trovato Emanuele, Virone Marco, Pellacani Giovanni, Potenza Concetta, Skroza Nevena
Аннотация
OBJECTIVE: To evaluate the association between psoriasis severity and comorbidities, assess the impact of biologic disease-modifying antirheumatic drugs (bDMARDs), in particular (adalimumab [ADA], risankizumab [RISA], secukinumab [SECU]) on CCI and estimate 10-year survival in psoriatic patients versus controls.
METHODS: In this multicenter cross-sectional study, 343 psoriasis patients and 343 matched controls from 13 Italian centers were analyzed. CCI scores and comorbidity profiles were stratified by disease severity PASI score [Psoriasis Area and Severity Index] and treatment groups. Survival probabilities were estimated using a predictive model.
RESULTS: Psoriasis patients had significantly higher age-adjusted CCI compared to controls (p = 0.021), particularly in severe cases (PASI >10; p = 0.003). Peripheral vascular disease, cerebrovascular disease, and myocardial infarction correlated with disease severity. ADA-treated patients showed lower CCI than those on RISA or SECU (p < 0.05). The estimated 10-year survival did not differ significantly between psoriasis and controls.
CONCLUSIONS: Psoriasis severity is associated with increased comorbidity burden, highlighting the importance of cardiovascular and metabolic screening. Biologic therapies may differentially affect comorbidity progression, supporting personalized treatment approaches.